Does Rallies show Form 4 insider transactions for URGN?

Yes. Rallies tracks URGN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is URGN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for URGN. It does not provide personalized investment advice.

URGN (UroGen Pharma Ltd. Ordinary Shares) Stock Analysis - Insider Trades

UroGen Pharma Ltd. Ordinary Shares (URGN) is a publicly traded Healthcare sector company. As of May 21, 2026, URGN trades at $29.96 with a market cap of $1.39B and a P/E ratio of -10.77. URGN moved +6.99% today. Year to date, URGN is +36.56%; over the trailing twelve months it is +300.80%. Its 52-week range spans $3.42 to $32.37. Analyst consensus is strong buy with an average price target of $39.29. Rallies surfaces URGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading URGN stock inside the company?

Recent URGN insider activity includes Schoenberg Mark sold 10.00K, Smith Jason Drew sold 2.65K, Smith Jason Drew sold 1.61K, Smith Jason Drew sold 3.22K, and Schoenberg Mark sold 1.84K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

URGN Key Metrics

Key financial metrics for URGN
Metric	Value
Price	$29.96
Market Cap	$1.39B
P/E Ratio	-10.77
EPS	$-2.74
Dividend Yield	0.00%
52-Week High	$32.37
52-Week Low	$3.42
Volume	7.31K
Avg Volume	0
Revenue (TTM)	$140.49M
Net Income	$-133.22M
Gross Margin	89.85%

Recent URGN Insider Trades

Schoenberg Mark sold 10.00K (~$300.00K) on May 8, 2026.
Smith Jason Drew sold 2.65K (~$52.26K) on Feb 3, 2026.
Smith Jason Drew sold 1.61K (~$31.66K) on Feb 3, 2026.
Smith Jason Drew sold 3.22K (~$63.34K) on Feb 3, 2026.
Schoenberg Mark sold 1.84K (~$36.31K) on Feb 3, 2026.

Latest URGN News

UroGen Raises Price Target to $39 After Q1 Sales Double to $29.2M — May 7, 2026
UroGen Launches LG-UTUC Luminaries, Honors Leaders in Care for 6,000-7,000 Annual Patients — Apr 8, 2026
UroGen Achieves 72.2% Two-Year Event-Free Rate with ZUSDURI — Mar 30, 2026
UroGen-Backed Survey Reveals 80% Fear Recurrence, Many Undergo 15+ Cystoscopies — Mar 13, 2026
UroGen Pharma Q4 Revenue $37.8M Beats Estimates, Narrows Loss to $0.54 — Mar 2, 2026

URGN Analyst Consensus

7 analysts cover URGN: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.29.

Common questions about URGN

Who is trading URGN stock inside the company?: Recent URGN insider activity includes Schoenberg Mark sold 10.00K, Smith Jason Drew sold 2.65K, Smith Jason Drew sold 1.61K, Smith Jason Drew sold 3.22K, and Schoenberg Mark sold 1.84K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for URGN?: Yes. Rallies tracks URGN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is URGN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for URGN. It does not provide personalized investment advice.